Integrated Diagnostics Holdings reaffirmed revenue guidance for the fiscal year 2023. Considering their strong first half results, the solid strategies in place, and the positive momentum enjoyed by the Egyptian and Jordian subsidiaries, the company reaffirms their guidance of full-year conventional revenue (excluding Covid-19-related contributions) year-on-year growth of around 30% for fiscal year 2023.